Pacific Edge Limited · NZX:PEB
Pacific Edge — Shareholder Meeting (August 2025)
51 slides from Pacific Edge's shareholder meeting presentation, Aug 6, 2025
Slide 1: 2025 Annual Shareholders' Meeting Presentation
2025 ANNUAL SHAREHOLDERS’ MEETING PRESENTATION Chris Gallaher Chairman Dr Peter Meintjes Chief Executive Officer 6 August 2025
Slide 2: Chairman's Address
CHAIRMAN’S ADDRESS CHRIS GALLAHER Chairman 2
Slide 3: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation has been prepared by Pacific Edge Limited (PEL) beyond PEL’s control and could cause actual results to differ from Effect of rounding solely to provide interested parties with further information those predicted. Variations could either be materially
Slide 4: Directors
DIRECTORS SARAH PARK ANATOLE MASFEN BRYAN WILLIAMS ANNA STOVE TONY BARCLAY 4
Slide 5: Agenda
AGENDA 1. CHAIRMAN’S ADDRESS 2. CHIEF EXECUTIVE’S ADDRESS 3. QUESTIONS 4. RESOLUTIONS 5. VOTING AND GENERAL BUSINESS 6. MEETING CLOSE 5
Slide 6: FY25 Strategic Gains Overshadowed by Medicare Non-Coverage
FY 25 STRATEGIC GAINS OVERSHADOWED BY MEDICARE NON-COVERAGE COMPANY DEFINING STRATEGIC MILESTONES Cxbladder Triage included in the American Urological Association (AUA) Microhematuria guideline 28,894 24,642 Medicare non-coverage determination made on stale GLOBAL TESTS1 COMMERCIAL evidence beca
Slide 7: Raising New Capital to Maintain Commercial Momentum
RAISING NEW CAPITAL TO MAINTAIN COMMERCIAL MOMENTUM Pacific Edge’s priority is to ensure it has the resources and capacity to capitalize on its recent clinical and commercial milestones, grow in non-Medicare channels and regain Medicare coverage - Placement: $16.073 million pledged, subject to appro
Slide 8: Chief Executive's Address
CHIEF EXECUTIVE’S ADDRESS DR PETER MEINTJES Chief Executive Officer 8
Slide 9: Value Creation Through Three Pillars
VALUE CREATION THROUGH THREE PILLARS INPUTS OUTPUTS EXCELLENT PATIENT EXPERIENCE OUR PEOPLE AND ACCURATE RESULTS OUR IP, KNOWLEDGE EARLY DETECTION AND AND EXPERIENCE CLINICALLY ACTIONABLE CARE OUR PROCESSES INNOVATION PIPELINE FOR CLINICAL APPLICATIONS OUR CLINICAL STUDIES INCLUSIVE WORKPLACE PARTNE
Slide 10: AUA Microhematuria Guideline Inclusion
AUA MICROHEMATURIA GUIDELINE INCLUSION A COMPANY-DEFINING STRATEGIC MILESTONE ACHIEVED IN FEBRUARY 2025 The 2025 amendment to the AUA microhematuria guideline supports the use of urine-based biomarkers for intermediate-risk patients as an alternative to a cystoscopy • Primary driver for the change i
Slide 11: Pacific Edge's Evidence Program Seeks to Change Clinical Practice
PACIFIC EDGE’S EVIDENCE PROGRAM SEEKS TO CHANGE CLINICAL PRACTICE AUDIENCE EVIDENCE USE HEALTHCARE PAYERS - Change Medical Policy (Medicare, Kaiser (practice) Permanente, Veterans Administration, private - Change Reimbursement payers, etc). Policy Guidelines change: - Healthcare Payer Medical and Re
Slide 12: Medicare Non-Coverage in April 2025 Inconsistent with AUA Guideline
MEDICARE NON-COVERAGE IN APRIL 2025 INCONSISTENT WITH AUA GUIDELINE AUA GUIDELINE INCLUSION PROVIDES THE BASIS FOR GREATER SUCCESS WITH COMMERCIAL PAYERS MEDICARE REIMBURSEMENT COMMENCED IN 2020 BUT CEASED IN 2025 • Medicare reimbursed Cxbladder tests >98% since 2020 at US$760 per test – these tests
Slide 13: Seeking Re-Coverage via LCD Reconsideration and Medicare Appeals
SEEKING RE-COVERAGE VIA LCD RECONSIDERATION AND MEDICARE APPEALS RECONSIDERATION REQUESTS UNDER REVIEW; APPEALS TO RELY ON GUIDELINE INCLUSION POSITIVE ENGAGEMENT WITH NOVITAS TO RESTORE COVERAGE FOR TRIAGE AND MONITOR • Cxbladder Triage: A reconsideration request was submitted to Novitas in March 2
Slide 14: Medicare Re-Coverage: Estimated Timelines
MEDICARE RE-COVERAGE: ESTIMATED TIMELINES COVERAGE DECISIONS, PRIOTIZATION AND TIMELINES ARE AT THE DISCRETION OF NOVITAS1 MEDICARE RECONSIDERATION REQUEST CATALYST 2025* 2026* Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 STRATA Study (May 2024) L39365 Reconsideration request (Triage) AUA Macrohematuria guideline (Feb 2
Slide 15: Planned Publications - Embedding Cxbladder in Clinical Practice
PLANNED PUBLICATIONS - EMBEDDING CXBLADDER IN CLINICAL PRACTICE MEDICARE RECONSIDERATION AND GUIDELINE INCLUSION REQUESTS (Novitas1 has 60 days to deem a reconsideration request valid. Opening an LCD is at the discretion of Novitas) Catalyst (published) Test and evidence standard (2) Expected date o
Slide 16: US Contracted Payer Demand Supports 2H Volume Growth
US CONTRACTED PAYER DEMAND SUPPORTS 2H 25 VOLUME GROWTH AUA GUIDELINE INCLUSION REMAINS AN UNTAPPED OPPORTUNITY US TOTAL TEST VOLUME1 9,000 • US commercial volumes in 2H 25 increased 2.7% against 1H 25 8,000 8,627 supported by contracted payer volumes 7,000 7,335 • Non-Medicare volumes represented 4
Slide 17: Progress on Commercial Payer Opportunities
PROGRESS ON COMMERCIAL PAYER OPPORTUNITIES MICROHEMATURIA PATIENTS SKEW YOUNGER WITH COMMERCIAL HEALTH INSURANCE • The AUA guideline recommends Triage for intermediate risk microhematuria patients – male patients are 40-59, while female patients are >60. This is expected to drive a shift in payer mi
Slide 18: Sales Performance Improvements Embedded in FY
SALES PERFORMANCE IMPROVEMENTS EMBEDDED IN FY 25 WE SEE UNEXPLOITED OPPORTUNITIES TO LEVERAGE THE AUA GUIDELINE US SALES FORCE EFFICIENCY • Sales force efficiency (total tests/average FTE) and clinical 40 403 406 commitment (tests/ordering clinician) fall in Q1 26 35 381 379 379 381 400 30 reflectin
Slide 19: Foundations for Growth - US Cash Collections Improve
FOUNDATIONS FOR GROWTH – US CASH COLLECTIONS IMPROVE REIMBURSEMENT & CASH COLLECTIONS – A CORE COMPETENCY • Despite the dip in 2H 25 Average Sales Price (ASP1) due to US COMMERCIAL TEST VOLUMES AND ASP* (US$) timing variances related to accruals and increased provisions against revenue, ASP per test
Slide 20: Medicare Price for Triage Plus Accelerates Path to Profitability
MEDICARE PRICE FOR TRIAGE PLUS ACCELERATES PATH TO PROFITABILITY DRAFT PRICE FOR TRIAGE PLUS OF US$1,018 PER TEST PUBLISHED MEDICARE COVERAGE NEEDED BEFORE FULL-SCALE COMMERCIAL LAUNCH • The Centers for Medicare & Medicaid Services (CMS) set draft price for Triage Plus of US$1,018 via its ‘Gapfill’
Slide 21: Driving Growth in Asia Pacific and Consolidating New Zealand
DRIVING GROWTH IN ASIA PACIFIC AND CONSOLIDATING NEW ZEALAND SEEKING A NATIONAL HEMATURIA EVALUATION PATHWAY IN NZ AUSTRALIA & ASIA PACIFIC • Quarterly total test volumes benefit from: • Southeast Asia is still in business development, and we are extending • Fewer evaluations and non-billable tests
Slide 22: Customer Experience Initiatives Delivering Value
CUSTOMER EXPERIENCE INTIATIVES DELIVERING VALUE DIGITALIZATION OF INFORMATION FLOWS EMBEDS CXBLADDER IN CLINICAL PRACTICE THE PACIFIC EDGE CUSTOMER PORTAL ENHANCING CXBLADDER’S EASE OF USE • We give customers options to connect with Pacific Edge to fit their needs with easy-to-use digital integratio
Slide 23: Launching Improved Products and IVD for International Markets
LAUNCHING IMPROVED PRODUCTS AND IVD FOR INTERNATIONAL MARKETS AN IVD PRODUCT MAY EXTEND THE MARKET OPPORTUNITY AND THE ‘MOAT’ AROUND CXBLADDER READYING FOR THE LAUNCH OF TRIAGE PLUS • Product development investments in digital systems to ensure scalable lab operations for Triage Plus • Simplifying C
Slide 24: Outlook
OUTLOOK RECENT CATALYSTS FOR STRONG GROWTH – VOLUME AND PRICING • AUA microhematuria guideline enables sales, marketing and reimbursement activities. We are determined to maximize this milestone through existing and new initiatives • Triage Plus draft pricing at US$1,018 supports stronger unit econo
Slide 25: Resolutions
CANCER DIAGNOSTICS gs | PacificEdge’ 25
Slide 26: Voting Instructions
VOTING INSTRUCTIONS mane wae + Get a Voting Card CANCER DIAGNOSTICS | PacificEdge” 8 pare Aska Question Geta Voting Card Exit Mesting (0800 200 220 & Downloads 2) B Notice of meeting ‘Aska Question even ticet Bi virtual Meeting Guide 26
Slide 27: Resolution 1: Auditors' Remuneration
RESOLUTION 1: AUDITORS’ REMUNERATION RESOLUTION “To authorise the Directors to fix the auditors’ remuneration for the ensuing year.” 27
Slide 28: Resolution 2: Re-election of Chris Gallaher
RESOLUTION 2: RE-ELECTION OF CHRIS GALLAHER RESOLUTION “That Chris Gallaher, who retires by rotation and is eligible for re-election, be re-elected as a Director of the Company.” 28
Slide 29: Resolution 3: Re-election of Sarah Park
RESOLUTION 3: RE-ELECTION OF SARAH PARK RESOLUTION “That Sarah Park, who retires by rotation and is eligible for re-election, be re-elected as a Director of the Company.” 29
Slide 30: Resolution 4: Re-election of Tony Barclay
RESOLUTION 4: RE-ELECTION OF TONY BARCLAY RESOLUTION “That Tony Barclay, who retires by rotation and is eligible for re-election, be re-elected as a Director of the Company.” 30
Slide 31: Resolution 5: Share Placement
RESOLUTION 5: SHARE PLACEMENT RESOLUTION “That the issue of 160,728,498 new Shares to Placement Participants at an issue price of $0.10 cents per new Share under the Placement, with such new Shares to rank equally on issue with all existing Shares, be approved for all purposes, including NZX Listing
Slide 32: Resolution 6: Directors' Remuneration Pool
RESOLUTION 6: DIRECTORS’ REMUNERATION POOL RESOLUTION “That the total annual non-executive Directors’ remuneration pool be increased to $628,000 per annum, effective from 1 April 2025 and applied retrospectively.” 32
Slide 33: Resolution 7: Issue of Shares to Directors
RESOLUTION 7: ISSUE OF SHARES TO DIRECTORS RESOLUTION “That the issue of up to 1,930,000 new Shares to non-executive Directors in lieu of the payment of additional Director remuneration in cash in respect of the period from 1 April 2025 to 31 March 2026 as described in the Explanatory Notes, with su
Slide 34: Proxy Voting Directions
PROXY VOTING DIRECTIONS RESOLUTION FOR OPEN AGAINST TOTAL 1. Auditors’ remuneration 366,678,481 (97.69%) 8,409,599 (2.24%) 275,480 (0.07%) 375,363,560 2. Re-election of Chris Gallaher 364,555,420 (97.11%) 8,435,768 (2.25%) 2,430,616 (0.65%) 375,421,804 3. Re-election of Sarah Park 366,296,037 (97.63
Slide 35: General Business
GENERAL BUSINESS uU o a. = a m -% ro} ©, CANCER DIAGNOSTICS 35
Slide 36: Meeting Close
CANCER DIAGNOSTICS gs | PacificEdge’ 36
Slide 37: Appendix
APPENDIX uU o a. = a m -% ro} ©, CANCER DIAGNOSTICS 37
Slide 38: Capital Raising Risks
CAPITAL RAISING RISKS uU o a. = a m -% ro} ©, CANCER DIAGNOSTICS 38
Slide 39: Key Risks
KEY RISKS Pacific Edge does not currently have Medicare coverage for its Cxbladder products. Medicare previously accounted for the majority of its US test volumes and, therefore, a significant percentage of Pacific Edge's revenue. Although Pacific Edge is confident that it will regain coverage for T
Slide 40: Key Risks (cont)
KEY RISKS (CONT) In the ordinary course of conducting its business, Pacific Edge is exposed to potential litigation and other proceedings, including through claims of intellectual property infringement or breach of agreements. If such proceedings are brought against Pacific Edge, Pacific Edge could
Slide 41: Pacific Edge - Background Information
PACIFIC EDGE – BACKGROUND INFORMATION 41
Slide 42: Pacific Edge's Global Reach
PACIFIC EDGE’S GLOBAL REACH 42
Slide 43: Pacific Edge Overview
PACIFIC EDGE OVERVIEW CXBLADDER OFFERS A SIGNIFICANT ADDRESSABLE GLOBAL MARKET ANNUALLY THE PATIENT CARE PATHWAY US$8.5b Global TAM1 ~7m ~3.5m ~1.1m ~90k ~750k Focus of our 340m US$4.4b Present with Referred for Receive Annual cases of Living with bladder cancer Population TAM growth efforts hematur
Slide 44: Sources and Assumptions - Total Addressable Market
SOURCES AND ASSUMPTIONS - TOTAL ADRESSABLE MARKET REGION STATISTIC SOURCE Population 341,762,685 https://www.census.gov/popclock/ Incidence of hematuria 7,000,000 Presentation from Dr Sia Daneshmand (Director of Urologic Oncology and Clinical Research, USC) July 2019 Referred for clinical workup 3,5
Slide 45: Hematuria Evaluation Five Year Clinical Studies Roadmap
HEMATURIA EVALUATION FIVE YEAR CLINICAL STUDIES ROADMAP Calendar Pre 2023 2024 2025 2026 2027 2028 year 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 DBL STRATA * DBL DRIVE * AUSSIE * microDRIVE * Pooled CV CREDIBLE * Legend: Pre-activation (docs, CTA etc) Publication Submit
Slide 46: Surveillance Five Year Clinical Studies Roadmap
SURVEILLANCE FIVE YEAR CLINICAL STUDIES ROADMAP Calendar Pre 2023 2024 2025 2026 2027 2028 year 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 “The 1800” LOBSTER * OCTOPUS Legend: Pre-activation (docs, CTA etc) Publication Submitted * SIV DBL Records review / follow-up Databa
Slide 47: Summary of Cxbladder Clinical Evidence
SUMMARY OF CXBLADDER CLINICAL EVIDENCE Publication or Study Population Sensitivity NPV Specificity Comment (Sn) (Sp) Synthetic Analytes Development dataset (n=987) including MH (38.7%) & GH (61.3%) producing defined Sn, NPV and Sp. TNR in AV Harvey et al., (2025) 93.6% 99.4% 90.8% MH + GH developmen
Slide 48: References Summary of Clinical Evidence
REFERENCES SUMMARY OF CLINICAL EVIDENCE References Comment Holyoake et al., (2008). Development of a Multiplex RNA Urine Test for the Detection and Stratification of Transitional Cell Carcinoma of the Bladder. Clin Cancer Feasibility of urine-based assay including biomarker discovery for urothelial
Slide 49: Key Clinical Advisors and Consultants
KEY CLINICAL ADVISORS AND CONSULTANTS Professor Yair Lotan, MD Associate Professor Katie Murray, DOMS, FACS Institution: UT Southwestern Medical Center Institution: NYU Langone Relationship: Consultant, CAB member, IIT PI, CT PI Relationship: Consultant, CAB member, Brief Bio: Published >500 article
Slide 50: Pacific Edge - Taking New Zealand Innovation Global
PACIFIC EDGE – TAKING NEW ZEALAND INNOVATION GLOBAL Aug 2021 Cxbladder reaches 70% public Feb 2025 healthcare Triage included coverage in NZ in AUA Micro- Nov 2023 hematuria Oct 2021 Kaiser guideline PEB raises Permanente Dec 2012 Dec 2014 $103.5m EMR Launch of Pacific Edge Launch of Apr 2025 (~US$7
Slide 51: For More Information
FOR MORE INFORMATION: Dr. Peter Meintjes Chief Executive Officer email: peter.meintjes@pelnz.com Grant Gibson Chief Financial Officer email: grant.gibson@pelnz.com Pacific Edge 87 St David Street, PO Box 56, Dunedin, New Zealand P +64 3 577 6733 Within NZ 0800 555 563 email: investors@pacificedge.co